SUBSCRIBE
SUBSCRIBE

Shuttle Pharmaceuticals

IN THE PRESS
Press Releases
Shuttle Pharma Enters into Sponsored Research Agreement with the University of California, San Francisco to Advance PSMA Development Program
December 20, 2024
 · 
4 min read
Press Releases
Shuttle Pharma Expands Patient Enrollment for Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma as UVA Cancer Center Doses Its First Patient
November 26, 2024
 · 
5 min read
Press Releases
Shuttle Pharma Provides Third Quarter 2024 Corporate Update
November 14, 2024
 · 
6 min read
Press Releases
Shuttle Pharma Pays Off Senior Secured Convertible Note
October 30, 2024
 · 
4 min read
Press Releases
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
October 30, 2024
 · 
4 min read
Press Releases
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
October 29, 2024
 · 
4 min read
Press Releases
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
October 28, 2024
 · 
2 min read
Press Releases
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
September 5, 2024
 · 
3 min read
Press Releases
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
August 28, 2024
 · 
2 min read
Press Releases
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
August 27, 2024
 · 
3 min read
Load More
JOBS